QIBA FDG-PET/CT Tech Ctte Update Call
20 July 2012 at 9 AM CT (GMT-5)

Call Summary

In attendance:

- Paul E. Kinahan, PhD (co-chair)
- Ling X. Shao, PhD (co-chair)
- Keith Allberg
- Michael M. Graham, MD, PhD
- Howard Higley, PhD
- John Hoffman, MD
- Martin Lodge, PhD
- Lawrence MacDonald, PhD
- Eric Perlman, MD
- John Wolodzko, PhD
- Brian Zimmerman, PhD
- RSNA
- Anne Smith, PhD
- Julie Lisiecki
- Madeleine McCoy
- John Wolodzko, PhD
- Timothy Turkington, PhD

Discussion

- Group reviewed latest draft version of the claim and made minor edits:
  - Claim: If Profile criteria are met, then tumor glycolytic activity as reflected by the maximum standardized uptake value (SUVmax) can be measured from FDG-PET/CT with a within-patient coefficient of variation of 12% for evaluable tumors and using the same scanner.
  - Revised claim language circulated to group for review post-call, 7/20.
- Caveats also revised; to be discussed further on next call.
- Dr. Perlman reminded the group that the claim is dependent on specifications that are laid out in the Profile.
- SUVmax to be the definitive measurement.
- Dr. Wahl’s references and UPICT protocol reference to be included in “evaluable tumors” in Appendix XX.

Assignments

- Group to review sections 6.4 and 6.5 on next call, (7/27)
- Group to review revised claim language prior to next call
- Dr. Cole will email list of acronyms to Dr. Kinahan
- Dr. Kinahan is reviewing the common data format mechanism relating to DICOM details (Appendix D)
- Dr. Kinahan to add draft phantom noise and resolution from UPICT to section 6.4
- Dr. Lodge to work on revised claim language – section II
- Dr. Yap is reviewing the Appendix G.2
- New action item: If targeting mid-August for Profile completion, FDA briefing document needs to be ready at same time

Next steps:

- Approach to addressing Public Comment needs further discussion

Next call: To continue discussion of the Draft Claim at 9 am (CT) July 27th.